Enterome to Present Data on OncoMimics™ Approach to Cancer Immunotherapy at EACR 2024

Paris, France – June 11 th , 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform , will present data on its innovative OncoMimics ™ approach to cancer therapy at the 2024 Annual Congress of the European Association for Cancer Research (EACR 2024), taking place June 10-13 in Rotterdam, Netherlands. The presentation describes Enterome’s OncoMimics ™ peptide-based immunotherapy, designed to harness the patient’s immune system to target and eliminate cancer cells. Dr. Alice Talpin, lead researcher, commented : “The OncoMimics ™ approach offers a promising strategy to enhance cancer immunity by overcoming the limitations of current vaccines. Our preclinical and clinical data underscore the ability of OncoMimics ™ peptides to elicit strong, durable immune responses, which could significantly improve patient outcomes.” Peptide-based immunotherapy offers significant potential against cancer by leveraging the body’s immune system to eliminate cancer cells, targeting tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Enterome innovative OncoMimics ™ therapies are based on the concept of molecular mimicry and cross-reactivity between commensal-derived synthetic peptides and tumor-associated antigens-derived peptides (TAAps) to evoke a CD8 + T cell response against tumors. Based on this approach, Enterome has developed a pipeline of drug candidates for the treatment of cancer, including EO2463, which is demonstrating a favorable safety profile with encouraging early signs of efficacy in a Phase 2 clinical trial (EONHL1-20/SIDNEY) for indolent non-Hodgkin lymphomas, and EO2401, which has successfully completed a Phase 2 clinical trial (EOGBM1-18/ROSALIE) in patients with recurrent glioblastoma. Highlights from the EACR 2024 poster presentation, entitled Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens : In humanized HLA-A2 murine models, OncoMimics ™ peptides (OMPs) trigger the expansion of cross-reactive OMP-/TAAp- specific CD8 + T cells with specific cytotoxic activity against tumor cells. Experiments conducted on HLA-A2 + healthy human peripheral blood mononuclear cells revealed a high prevalence of cross-reactive OMP-/TAAp-specific CD8 + T cells when stimulated in vitro. In addition, those cross-reactive CD8 + T cells exhibit cytolytic activity against target cells presenting homologous TAAs. Abstract #1155 is published in an online supplement to Molecular Oncology (Volume 18, Issue S1, DOI: 10.1002/1878-0261.13683) and the Poster will be available on Enterome’s website following the session. Poster #1155 Presentation details Title : Innovative immunotherapy based on commensal-derived peptides for enhancing CD8+ T cell activation against Tumor-Associated Antigens Presenting Author : Alice Talpin, PhD, Enterome researcher Poster Session: Immunotherapy (odd Abstract Numbers) Poster Board: P-285 Session Date and Time: June 12, 18:40 to 20:15 CET (poster displayed from 11:00 CET) Download the press release (.pdf format) Enterome Headquarters 94/96 avenue Ledru-Rollin 75011 Paris – France Tel: +33 (0)1 75 77 27 85 Email: [email protected] Metro Station: Ledru-Rollin (Line 8) About About us Leadership Investors Pipeline Pipeline OncoMimics™ Platform Our Mimicry Approach Our Drug Discovery Platform Clinical Trials B cell malignancies Glioblastoma Adrenal tumors Colorectal Cancer News & Events Press Releases Press Coverage Webinars Presentations & Posters Relevant Literature Careers Our Values Careers Cookies Policy Privacy Policy Legal Notice

The release as fetched from its publisher. enterome.com ↗